Overview

TCEB1 is altered in 1.34% of all cancers with breast invasive ductal carcinoma, prostate adenocarcinoma, invasive breast carcinoma, lung adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in TCEB1 are TCEB1 Amplification (1.27%), TCEB1 A96G (0.05%), TCEB1 T41M (0.02%), TCEB1 Y79C (0.01%), and TCEB1 S71L (0.01%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.